Asthma UK Scotland Comment On The SMC’s Approval Of Omalizumab (Xolair) For The Treatment Of Children Aged 6-12 With Severe, Allergic Asthma
Rosie Newbigging, Asthma UK’s Executive Director of Nations, Regions & Services, says: ‘Asthma UK Scotland fought hard for Xolair to become available for adults and teenagers with severe, allergic asthma in 2007, so we are delighted that the Scottish Medicines Consortium (SMC) has extended the use of this life-changing drug for the treatment of children aged six to twelve…
(more...)